What actually makes Wegovy work — and why it's more than willpower

The biggest myth: Wegovy is just an appetite suppressant you push through

People often arrive at a Wegovy conversation having heard it described as a drug that makes you feel sick so you eat less. That framing isn't accurate, and it misses most of what is happening.

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating, sending a satiety signal to the hypothalamus and other brain regions that regulate hunger. In people with obesity, that signalling pathway tends to be blunted. Semaglutide doesn't create an artificial aversion to food; it restores and amplifies a system that was already meant to be there. You can read a plain-language explanation of how this works on the NHS semaglutide medicines page.

Gastric emptying also slows, meaning food leaves the stomach more gradually. That lengthens the feeling of fullness after a meal without requiring a larger portion. Neither of these effects is about motivation or discipline. They are physiological shifts. That distinction matters because it changes how people understand (and stick with) treatment.

Nausea does occur, particularly early on or after a dose increase, and it is a real side effect rather than the intended mechanism. The dose titration schedule exists partly to give the body time to settle. Our Wegovy overview covers the titration pathway in more detail.

Why the titration schedule is doing more work than most people realise

Wegovy starts at 0.25 mg weekly. That is not a therapeutic dose in the sense of producing significant weight loss, its job is acclimatisation. The body adjusts to the medicine's effect on gastric motility before the dose climbs. The standard schedule moves through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each level.

This matters for understanding how Wegovy works because the medicine's effect builds across those months rather than switching on at full strength. People who expect rapid early results sometimes become discouraged at the lower doses. The weight loss that appears in trial data (around 15% on average at 68 weeks) is the cumulative result of sustained hormonal signalling at the maintenance dose, not a quick response to a starter pen.

Novo Nordisk, the company behind Wegovy, has more recently had a 7.2 mg higher-maintenance dose approved by the MHRA, with trials reporting around 20.7% average weight reduction over 72 weeks. The titration principle remains: a prescriber guides the schedule, and evidence checks are part of any dose increase at a regulated pharmacy.

If you are wondering how Wegovy fits into your working week (whether you can keep to a weekly injection alongside a busy schedule, holiday travel, or the unpredictability of shift work) that is worth raising at your consultation. Taking Wegovy to work is something our prescribers can advise on directly.

Side effects that tell you the medicine is working, and ones worth monitoring

Because semaglutide slows gastric emptying, the most common early side effects are gastrointestinal. Nausea, loose stools, constipation, bloating and indigestion are all reported, typically peaking in the days after a dose increase before easing. Some people also notice increased gas or feelings of fullness that last well into the afternoon after a modest breakfast. These are signs the medicine is doing what it is designed to do, not signals that something has gone wrong.

There are rarer effects worth being aware of. A small number of people on GLP-1 medicines report feeling consistently cold, which may reflect changes in metabolic rate or reduced calorie intake. If that sounds familiar, our page on feeling cold on Wegovy explains what the evidence says.

More seriously, acute pancreatitis is a known but infrequent side effect. Severe stomach pain that radiates toward the back, with or without vomiting, is a reason to seek urgent medical attention rather than wait for your next appointment. The MHRA highlighted this in a Drug Safety Update in January 2026. Side effects can also be reported directly using the MHRA Yellow Card scheme.

Wegovy is a prescription-only medicine. A prescriber reviews whether your medical history, any existing conditions and other medicines make it a suitable option. Pregnancy, breastfeeding, and trying to conceive are reasons it is not recommended; under-18s are outside the licensed age range. These are decisions made with a clinician, not defaults to assume.

What 'it worked in trials' means for real people

The STEP 1 trial randomised nearly 2,000 adults with obesity or overweight plus a weight-related condition to semaglutide 2.4 mg or placebo alongside lifestyle support, over 68 weeks. Average weight reduction in the semaglutide group was around 15%. That figure is an average across the population, some participants lost considerably more, others less. The trial was conducted with structured lifestyle support, which is why clinical guidance pairs the medicine with dietary and activity changes rather than treating it as standalone.

The question of what Wegovy costs privately is reasonable alongside understanding the evidence, and the two are connected: a legitimate private prescription includes clinical review and ongoing monitoring, which is part of what supports the outcomes seen in trials. Cutting corners on clinical oversight is not a way to replicate those results.

If you would like to talk through whether Wegovy is clinically suitable for you, our prescribers review consultations the same day, Monday to Friday. There is no waiting list. Start your free consultation when you are ready, there is no pressure to proceed.